Mutational landscape of chronic myeloid leukemia: more than …
We highlight the effects of somatic mutations involving certain genes (e.g. epigenetic modifiers) on the outcomes of TKI treatment. We also discuss the potential value of incorporating genetic data in treatment decisions and the routine care of CML patients as a future direction for optimizing CML management.
Spectrum of somatic mutation dynamics in chronic myeloid leukemia ...
2017年1月5日 · Somatic mutations commonly detected in a variety of myeloid neoplasms have not been systematically investigated in chronic myeloid leukemia (CML). We performed targeted deep sequencing on a total of 300 serial samples from 100 CML patients; 37 patients carried mutations. Sixteen of these had evidence of mutations originating from preleukemic ...
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia ...
2011年8月4日 · Mutations in the Bcr-Abl kinase domain may cause, or contribute to, resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia patients. Recommendations aimed to rationalize the use of BCR-ABL mutation testing in chronic myeloid leukemia have been compiled by a panel of experts appointed by the European LeukemiaNet (ELN) and ...
Chronic Myelogenous Leukemia - StatPearls - NCBI Bookshelf
2023年1月16日 · Chronic myelogenous leukemia (CML), BCR-ABL1-positive, is classified as a myeloproliferative neoplasm predominantly composed of proliferating granulocytes and determined to have the Philadelphia chromosome/translocation t(9;22)(q34;q11.2). CML affects both the peripheral blood and the bone marrow.
Genetic Biomarkers in Chronic Myeloid Leukemia: What Have …
The presences of chromosomal aberrations and small DNA mutations are thought to be associated with the progression of a relatively benign CML-CP to the aggressive CML-BP .
Full article: Mutational landscape of chronic myeloid leukemia: …
In this article, we will review current knowledge about the mutational profile in different phases of CML as well as patterns of mutational dynamics in patients having different outcomes. We highlight the effects of somatic mutations involving certain genes (e.g. epigenetic modifiers) on the outcomes of TKI treatment.
Chronic myeloid leukemia kinase domain mutations: A …
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm that harbors the Philadelphia chromosome. Tyrosine kinase inhibitor (TKI) therapy has dramatically improved the survival of patients with CML. Nevertheless, 20%–40% of CML patients require changes in TKI therapy due to intolerance or drug resistance.
Genetic landscape of chronic myeloid leukemia
2022年12月7日 · Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by the BCR::ABL1 fusion gene, which aberrantly activates ABL1 kinase and promotes the overproduction of leukemic cells. CML typically develops in the chronic phase (CP) and progresses to a blast crisis (BC) after years without effective treatment.
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML…
2022年4月20日 · Several recent studies have reported the association of somatic mutations involving cancer-associated genes with treatment outcome in chronic phase (CP) CML [7, 8, 9, 10]. Mutations in...
Mutation accumulation in cancer genes relates to nonoptimal …
2020年2月2日 · High mutational load and variants in cancer genes predicts nonoptimal treatment outcome and are new independent prognostic markers of CML. Dysregulation of DNA repair and the JAK-STAT signaling pathways relates to progression. Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm accounting for ∼15% of all leukemia.